Inovio Pharmaceuticals Inc INO shares are trading lower Tuesday after the company announced the pricing of a public offering.
What Happened: Inovio announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share. The company will also offer pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant.
All of the securities are being offered and sold by Inovio. The offering is expected to close on or about April 18. Inovio said it anticipates gross proceeds of approximately $36 million.
Inovio is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.
See Also: What’s Going On With Italian Energy Company Eni Shares Today?
How To Buy INO Stock
By now you're likely curious about how to participate in the market for Inovio – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Inovio, which is trading at $8.38 as of publishing time, $100 would buy you 11.93 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
INO Price Action: Inovio shares were down 23.9% at $8.36 at the time of publication, according to Benzinga Pro.
Photo: 3844328 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.